“Taken together, the results of this study add to the cumulative evidence in support of plant-based MC (medical cannabis) as a safe and effective treatment option and potential opioid substitute or augmentation therapy for the management of chronic pai…
Category: research
CDC Still Soliciting Comments Regarding Chronic Pain Management Solutions
The Centers for Disease Control and Prevention is still seeking public comments on how Americans with chronic pain are successfully treating their symptoms. The deadline to submit comments to the agency is Tuesday, June 16, 2020.
Scientific Review Concludes That Cannabis Consumers Are at No Greater Risk of Occupational Injuries
“Suspicionless marijuana testing never has been an evidence-based policy. Rather, these discriminatory practices are a holdover from the zeitgeist of the 1980s ‘war on drugs.’ But times have changed; attitudes have changed, and in many places, the marijuana laws have changed. It is time for workplace policies to adapt to this new reality.”
Clinical Trial: Cannabinoid Administration Via a Metered-Dose Inhaler Is Safe and Effective for Chronic Pain Patients
“This feasibility trial demonstrated that a metered-dose cannabis inhaler delivered precise and low THC doses [that] produced a dose-dependent and safe analgesic effect in patients with neuropathic pain/complex-regional pain syndrome.”
Analysis: Adult-Use Marijuana Legalization Associated with Tourism Spike
“[L]egalization in Colorado is associated with an increase of nearly 51,000 hotel rooms rented per month [and] once commercial sale is permitted, there is an increase of almost 120,000 room rentals per month.”
CDC Seeks Public Comments Regarding Chronic Pain Management
“Interested persons or organizations are invited to participate by submitting written views, recommendations, and data related to perspectives on and experiences with pain and pain management. CDC invites comments specifically on topics focused on using or prescribing opioid pain medications, non-opioid medications, or non-pharmacological treatments.”
NORML Formally Responds to DEA’s Proposed Changes to Marijuana Cultivation Rules
“We believe that the adoption of these rules may further stonewall efforts to advance our scientific understanding of cannabis by unduly expanding the DEA’s authority and control over decisions that ought to be left up to health experts and scientists.”
Study: Far Fewer Incidences of Vaping Illness Reported in States with Legal Cannabis Markets
“Just like alcohol prohibition gave rise to the illicit production of dangerous ‘bathtub gin,’ marijuana prohibition provides bad actors, not licensed businesses, the opportunity to fulfill consumers’ demand – sometimes with tragic results.”
NORML Says DEA’s Newly Proposed Bulk Cultivation Rules Are “Unduly Onerous, Expensive, and Impractical”
“These new rules are unduly onerous, expensive, and impractical. Even if they are ultimately implemented, it is unlikely that they would greatly facilitate clinical cannabis research in the United States.”
Clinical Trial: Oral THC Administration Associated with Opioid-Sparing Effects
Authors reported that patients administered oral THC experienced a “nine-fold greater reduction in opioid consumption” compared to controls.